Independent Advisor Alliance Neurocrine Biosciences Inc Transaction History

Independent Advisor Alliance

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	SELL	$92.03 - $107.81 $36,627 - $42,908	-398 Reduced 16.62%	1,996 $212,000
Q2 2022 Aug 04, 2022	SELL	$75.79 - $100.07 $29,861 - $39,427	-394 Reduced 14.13%	2,394 $233,000
Q1 2022 May 06, 2022	SELL	$72.45 - $94.81 $25,574 - $33,467	-353 Reduced 11.24%	2,788 $261,000
Q4 2021 Feb 11, 2022	SELL	$79.65 - $106.22 $40,223 - $53,641	-505 Reduced 13.85%	3,141 $268,000
Q3 2021 Nov 01, 2021	SELL	$86.18 - $99.03 $49,467 - $56,843	-574 Reduced 13.6%	3,646 $350,000
Q2 2021 Aug 12, 2021	BUY	$89.43 - $102.27 $1,430 - $1,636	16 Added 0.38%	4,220 $411,000
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $525 - $716	6 Added 0.14%	4,204 $409,000
Q4 2020 Feb 11, 2021	BUY	$86.91 - $108.33 $3,041 - $3,791	35 Added 0.84%	4,198 $402,000
Q3 2020 Nov 04, 2020	BUY	$96.16 - $135.15 $90,486 - $127,176	941 Added 29.21%	4,163 $400,000
Q2 2020 Aug 06, 2020	BUY	$85.09 - $130.36 $274,159 - $420,019	3,222 New	3,222 $393,000

654

96.5M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.4B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Independent Advisor Alliance, based on Form 13F filings with the SEC.

Stay updated on Independent Advisor Alliance with notifications on news.